QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:AXLA

Axcella Health (AXLA) Stock Forecast, Price & News

$0.33
-0.01 (-2.98%)
(As of 06/7/2023 ET)
Compare
Today's Range
$0.32
▼
$0.35
50-Day Range
$0.33
▼
$0.50
52-Week Range
$0.16
▼
$2.79
Volume
37,686 shs
Average Volume
646,546 shs
Market Capitalization
$24.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Axcella Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,510.4% Upside
$5.25 Price Target
Short Interest
Bearish
5.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.49) to ($1.35) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.33 out of 5 stars

Medical Sector

935th out of 981 stocks

Biological Products, Except Diagnostic Industry

152nd out of 159 stocks

See Top Rated MarketRank™ Stocks Here

AXLA stock logo

About Axcella Health (NASDAQ:AXLA) Stock

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Stock News Headlines

May 12, 2023 | americanbankingnews.com
HC Wainwright Brokers Lift Earnings Estimates for Axcella Health Inc. (NASDAQ:AXLA)
May 8, 2023 | markets.businessinsider.com
Axcella Health (AXLA) Gets a Hold from H.C. Wainwright
June 7, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
April 17, 2023 | finance.yahoo.com
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
April 14, 2023 | finance.yahoo.com
Big Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top Stories
April 14, 2023 | msn.com
Long COVID-Fatigue Impacts 50M People - Axcella Health Seeks Funding To Support Drug Development
April 5, 2023 | americanbankingnews.com
Q2 2023 Earnings Forecast for Axcella Health Inc. (NASDAQ:AXLA) Issued By HC Wainwright
April 4, 2023 | americanbankingnews.com
Axcella Health Inc. Forecasted to Earn FY2027 Earnings of ($1.38) Per Share (NASDAQ:AXLA)
June 7, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
April 3, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Hold Rating on Axcella Health (AXLA)
April 1, 2023 | benzinga.com
Axcella Health Q4 EPS $(0.33) Misses $(0.30) Estimate; Cash & Cash Equivalents Of Sufficient To Operate Into Q2 Of 2023
April 1, 2023 | americanbankingnews.com
Axcella Health Inc. (NASDAQ:AXLA) Short Interest Update
March 30, 2023 | benzinga.com
Axcella Health shares are trading higher after the company reported Q4 financial results.
March 30, 2023 | finance.yahoo.com
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 16, 2023 | markets.businessinsider.com
Noble Financial Keeps Their Buy Rating on Axcella Health (AXLA)
February 16, 2023 | msn.com
Why Is Axcella Health (AXLA) Stock Up 35% Today?
February 15, 2023 | finance.yahoo.com
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
February 9, 2023 | finance.yahoo.com
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference
January 25, 2023 | finance.yahoo.com
With lean staff, low cash, Axcella races ahead with Long Covid drug
January 24, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Hold Rating on Axcella Health (AXLA)
January 24, 2023 | investorplace.com
Why Is Axcella Health (AXLA) Stock Up 66% Today?
January 23, 2023 | marketwatch.com
Axcella Health Shares Surge 53% on U.K. Regulator Guidance on AXA1125 for Long Covid Fatigue
January 23, 2023 | finance.yahoo.com
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
December 23, 2022 | finance.yahoo.com
Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85%
December 15, 2022 | finance.yahoo.com
Axcella Announces Program Reprioritization and Corporate Restructuring
November 11, 2022 | finance.yahoo.com
Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
November 4, 2022 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Axcella Health (AXLA)
See More Headlines

AXLA Price History

AXLA Company Calendar

Last Earnings
3/30/2023
Today
6/07/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXLA
CUSIP
N/A
CIK
1633070
Web
www.axcellahealth.com
Phone
(857) 320-2200
Fax
617-441-6243
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,521.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-81,190,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-3,888.62%
Return on Assets
-229.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.07
Quick Ratio
1.07

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.06 per share
Price / Book
5.40

Miscellaneous

Outstanding Shares
73,690,000
Free Float
68,897,000
Market Cap
$23.85 million
Optionable
Not Optionable
Beta
1.56

Key Executives

  • William R. HinshawWilliam R. Hinshaw
    President, Chief Executive Officer & Director
  • Margaret Koziel
    Chief Medical Officer & Senior Vice President
  • Paul Fehlner
    Secretary, Chief Legal Officer & Senior VP
  • Dan Kirby
    SVP-Strategic Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AXLA Stock - Frequently Asked Questions

Should I buy or sell Axcella Health stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings or view top-rated stocks.

What is Axcella Health's stock price forecast for 2023?

4 brokers have issued 12 month target prices for Axcella Health's shares. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they predict the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 1,521.9% from the stock's current price.
View analysts price targets for AXLA or view top-rated stocks among Wall Street analysts.

How have AXLA shares performed in 2023?

Axcella Health's stock was trading at $0.3275 at the beginning of 2023. Since then, AXLA shares have decreased by 1.2% and is now trading at $0.3237.
View the best growth stocks for 2023 here.

When is Axcella Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our AXLA earnings forecast.

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) announced its earnings results on Thursday, March, 30th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.06.

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.46%), Virtu Financial LLC (0.11%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane and William Hinshaw.
View institutional ownership trends.

How do I buy shares of Axcella Health?

Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $0.32.

How much money does Axcella Health make?

Axcella Health (NASDAQ:AXLA) has a market capitalization of $23.85 million. The company earns $-81,190,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.

This page (NASDAQ:AXLA) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -